Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity
The lipid composition of the plasma membrane defines the localisation of KRAS and its oncogenic function. Here the authors show that EFR3A binds to active KRAS to recruit PI4KA and alters the lipid composition of the plasma membrane to promote KRAS oncogenic signalling and tumorigenesis.
Guardado en:
Autores principales: | Hema Adhikari, Walaa E. Kattan, Shivesh Kumar, Pei Zhou, John F. Hancock, Christopher M. Counter |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b15aa2d411704499ade6c2c0e8aff6f3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability
por: Hema Adhikari, et al.
Publicado: (2018) -
Oncogenic KRAS: Signaling and Drug Resistance
por: Hyeon Jin Kim, et al.
Publicado: (2021) -
A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
por: Nicolas Bery, et al.
Publicado: (2020) -
Immune modulatory effects of oncogenic KRAS in cancer
por: Shaima’a Hamarsheh, et al.
Publicado: (2020) -
Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis
por: Liu X, et al.
Publicado: (2019)